



HAL
open science

Efficacy of aztreonam with β -lactamase inhibitors against metallo-carbapenemase-producing Enterobacteria

M. Danjean, F. Morel, J. Robert

► **To cite this version:**

M. Danjean, F. Morel, J. Robert. Efficacy of aztreonam with β -lactamase inhibitors against metallo-carbapenemase-producing Enterobacteria. *Infectious Diseases Now*, 2021, 10.1016/j.idnow.2021.02.005 . hal-03205859

HAL Id: hal-03205859

<https://hal.sorbonne-universite.fr/hal-03205859v1>

Submitted on 22 Apr 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

[Click here to view linked References](#)

1 **Title:** Brief Report: Efficacy of aztreonam with β -lactamase inhibitors against metallo-carbapenemase-
2 producing Enterobacteria

3 **Article Type:** Brief Report

4 **Author names and affiliations:** M. Danjean¹, F. Morel^{1,2}, J. Robert^{1,2}

5 ¹ Service de Bactériologie et Hygiène, APHP.Sorbonne Université, Site Pitié-Salpêtrière, Paris, France

6 ² Centre d'Immunologie et des Maladies Infectieuses, Inserm, Sorbonne Université (U1135 – E2), Paris, France

7 **Corresponding Author:** Pr. Jérôme Robert

8

9 **Corresponding Author's Institution:**

10 Service de Bactériologie-Hygiène Hospitalière, APHP.Sorbonne Université, Site Pitié-Salpêtrière

11 47-83 bd de l'hôpital, 75013 PARIS

12 +33 1 42 16 20 70

13 jerome.robert@aphp.fr

14

15 **Keywords:** Carbapenemase-producing Enterobacteriaceae ; ceftazidime-avibactam ; ceftolozane-tazobactam ;
16 aztreonam ; synergy.

17 **Declarations**

18 Funding: none.

19 Conflicts of interests: none.

20 Availability of data and material: The authors can provide the summary table of the microbiological collection.

21 Code availability: Not applicable.

22

23

24

25 **Abstract**

26

27 **Purpose:** The combination of aztreonam (ATM), poorly hydrolyzed by metallo- β -lactamase (MBL) and β -
28 lactamase inhibitors inhibiting extended spectrum β -lactamases represents a theoretical therapeutic option
29 against carbapenemase-producing Enterobacteriaceae (CPE). We evaluated the *in vitro* activity of aztreonam
30 combined with ceftazidime-avibactam (CZA) or ceftolozane-tazobactam (C/T) against MBL CPE.

31 **Methods:** The effects of the combinations were tested against 42 clinical MBL CPE resistant to ATM by using
32 E-test strips.

33 **Results:** CZA and ATM were synergistic and restored ATM susceptibility in 26/42 isolates (average MIC gain:
34 11-fold), while the second combination was poorly active.

35 **Conclusion:** CZA+ATM needs further evaluation for treating patients with MBL CPE.

36

37 Sir,

38

39 Metallo- β -lactamases (MBL) produced by Enterobacteriaceae inhibit the clinical activity of most β -lactams but
40 aztreonam (ATM). However, carbapenemase-producing Enterobacteriaceae (CPE) are frequently carrying
41 additional resistance mechanisms such as extended-spectrum- β -lactamase (ESBL) or over-production of
42 chromosomally-determined cephalosporinase conferring additional resistance to ATM. Hence, such isolates
43 represent a therapeutic challenge. Some hope comes from the combination of ATM with ceftazidime-avibactam
44 (CZA), which has recently demonstrated *in vitro* and *in vivo* activities on MBL-producing Enterobacteriaceae
45 [1–4]. Therefore, we assessed the *in vitro* synergistic activity of two antibiotic combinations with ATM, *i.e.*
46 CZA and ceftolozane-tazobactam (C/T). Unselected MBL CPE isolates were consecutively collected from
47 clinical samples from 2016 to 2019 in a University hospital in Paris, France. The phenotypic test Resist-4 OKNV
48 (Coris Bioconcept[®], Gembloux, Belgium) and the genotypic test Xpert Carba-R (Cepheid[®], Sunnyvale USA)
49 were used to characterize carbapenemase enzymes. MICs of ATM, CZA, and C/T were determined by the E-test
50 strip method (BioMérieux[®], Durham, USA – Liofilchem[®], Waltham, USA). The synergistic activities of the
51 ATM-CZA and ATM-C/T combinations were determined as previously described [1], by first applying on a
52 Mueller-Hinton agar the CZA or C/T strip, that was replaced after 10 minutes, by an ATM strip at the very same
53 place. Plates were incubated at 37°C for 16 – 18 hours under aerobiosis conditions. The MICs of the
54 combinations were interpreted according to the 2018 EUCAST (<http://www.eucast.org>) breakpoints for ATM (1
55 and 4 mg/L). In order to quantify the decrease in MICs values of the synergistic combinations as compared to
56 ATM alone, values of MICs \geq 256 mg/L were converted to 512 mg/L. ESBL-production was assessed by the
57 double-disk diffusion method ⁴. The median decreases in MIC dilutions were compared by using the Mann
58 Whitney test (R project, version 4.0.0).

59 A total of 47 MBL-producing Enterobacteriaceae (37 NDM and 10 VIM) were collected. *Escherichia coli* was
60 the most frequent species (43%), followed by *Klebsiella pneumoniae* (26%) and *Enterobacter cloacae complex*
61 (17%). Other species were *Citrobacter freundii* (n=4), *C. koseri* (n=1), *K. oxytoca* (n=1) and *Proteus mirabilis*
62 (n=1). A total of 73% (27/37) of NDM- and half (5/10) of VIM-producing isolates displayed an ESBL
63 phenotype. According to EUCAST breakpoints, all isolates were resistant (R) to CZA and C/T, and five were
64 ATM-susceptible (S). ATM-CZA and ATM-C/T combinations MICs distribution were firstly plotted (see Figure
65 1) as a global visualization purpose and to seek the impact of the additive ESBL-producing phenotype. As
66 expected, the five ATM-S isolates remained ATM-CZA-S and ATM-C/T-S. Among the 42 ATM non-S isolates,

67 only four (9%) were ATM-C/T-S, whereas 26 (62%) were ATM-CZA-S and 12 (29%) of intermediate
68 susceptibility to ATM-CZA (as shown in Figure 2). There was no significant difference between ESBL and non-
69 ESBL isolates. Among the four ATM-CZA-R (MICs > 256 and 128 mg/L) isolates, two (one NDM and one
70 VIM producer) were ATM-C/T-S (MICs: 0.38 and 0.19 mg/L), both displaying an ESBL phenotype. The
71 confidence interval of MICs distribution among all MBL-producing Enterobacteriaceae for ATM-CZA and
72 ATM-C/T were respectively [0 ; 34.47] and [48.04 ; 137.08] (p-value < 0.05).

73 Amongst the two ATM-CZA-R remaining isolates, one was of intermediate susceptibility and one was resistant
74 to ATM-C/T. Among the 30 ATM-C/T-R isolates, 17 (57%) were ATM-CZA-S. The median reduction in MICs
75 dilution for the combinations with ATM were 14 (range: 0 to 24) fold for ATM-CZA compared to 5 (range: 0 to
76 22) fold for ATM-C/T and the difference was statistically significant (p < 0.05). However, for only three isolates
77 (VIM-positive *E. coli*; NDM-positive *K. pneumoniae*; NDM and ESBL-positive *E. cloacae*), the decrease in
78 MICs was higher with the ATM-C/T than with the ATM-CZA combination.

79 In summary, by using a set of unselected clinical isolates, we confirmed the interest of the ATM-CZA
80 combination, while the ATM-C/T combination was seldom synergistic. Of interest, ESBL production had no
81 impact on the MIC of the ATM-CZA combination. Of note, even though the ATM-C/T combination appeared of
82 minimal interest, the latter may warrant testing when the ATM-CZA combination is ineffective. Indeed, two of
83 four of the ATM-CZA-R strains appeared to be susceptible to the ATM-C/T combination. In the latter cases,
84 there was no obvious link between the synergistic effect of ATM-C/T and the resistance phenotypic pattern of
85 the isolates. Our report confirms previous studies on the interest of the ATM-AVI (avibactam) combination on
86 MBL [1,2,4–7]. Nevertheless, besides one study [5] we tested a larger number of species and included VIM
87 MBL. Because AVI has no inhibitory activity against MBL ⁵, the efficacy of the combination is likely due to the
88 inhibition of class A or class C β -lactamases by AVI, including carbapenemases ³ thus protecting ATM from
89 hydrolysis by these enzymes. We report also herein on the new combination C/T and demonstrated its limited
90 interest in this purpose.

91 Because new β -lactamase inhibitors combined to carbapenems have little *in vitro* efficacy against MBL CPE, our
92 results advocate for discussing the clinical use of the ATM-CZA combination as salvage therapy when no
93 alternatives are available for the treatment of infections due to MBL-producing isolates.

94

95

96 **Figure 1 – Distribution of MIC values**

97 Minimum inhibitory concentration (MIC) distributions of ceftazidime-avibactam (CZA), and ceftolozane-
98 tazobactam (C/T) in combination with aztreonam (ATM) against metallo- β -lactamase producing isolates. White
99 and grey bars represent ATM-CZA and ATM-C/T MICs, respectively. Dotted and solid bars represent extended
100 spectrum β -lactamase- (ESBL) and non-ESBL-producing isolates, respectively. The two vertical solid lines
101 represent the lower (1 mg/L) and higher (4 mg/L) ATM clinical breakpoints.

102

103 **Figure 2 – Scatter plot of Minimum Inhibitory Concentrations (MIC) of combinations with aztreonam**

104 Minimum inhibitory concentration (MIC) values of aztreonam + ceftazidime-avibactam (ATM-CZA) plotted
105 against aztreonam + ceftolozane-tazobactam (ATM-C/T) on a double-logarithmic scale. The lower and higher
106 clinical breakpoints (www.eucast.org) of ATM are represented by the two solid black lines on each axes (1 and 4
107 mg/L, respectively).

108 Grey and black dots represent one and two isolates, respectively

109

110

111

112

113 **References**

114

- 115 1. Emeraud C, Escaut L, Boucly A, Fortineau N, Bonnin RA, Naas T, et al. Aztreonam plus Clavulanate,
116 Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo- β -Lactamase-Producing Gram-
117 Negative Bacteria. *Antimicrob. Agents Chemother.* [Internet] 2019 11 [cited 2019 5];63. doi:
118 <http://aac.asm.org/lookup/doi/10.1128/AAC.00010-19>doi: 10.1128/AAC.00010-19
- 119 2. Jayol A, Nordmann P, Poirel L, Dubois V. Ceftazidime/avibactam alone or in combination with aztreonam
120 against colistin-resistant and carbapenemase-producing *Klebsiella pneumoniae*. *J. Antimicrob. Chemother.*
121 2018 1;73:542–4. doi: 10.1093/jac/dkx393
- 122 3. Avery LM, Nicolau DP. Assessing the in vitro activity of ceftazidime/avibactam and aztreonam among
123 carbapenemase-producing Enterobacteriaceae: Defining the zone of hope. *Int. J. Antimicrob. Agents*
124 2018;52:688–91. doi: 10.1016/j.ijantimicag.2018.07.011
- 125 4. Wenzler E, Deraedt MF, Harrington AT, Danizger LH. Synergistic activity of ceftazidime-avibactam and
126 aztreonam against serine and metallo- β -lactamase-producing gram-negative pathogens. *Diagn. Microbiol.*
127 *Infect. Dis.* 2017;88:352–4. doi: 10.1016/j.diagmicrobio.2017.05.009
- 128 5. Chew KL, Tay MKL, Cheng B, Lin RTP, Octavia S, Teo JWP. Aztreonam-Avibactam Combination
129 Restores Susceptibility of Aztreonam in Dual-Carbapenemase-Producing Enterobacteriaceae. *Antimicrob.*
130 *Agents Chemother.* 2018;62. doi: 10.1128/AAC.00414-18
- 131 6. Rossi F, Cury AP, Franco MRG, Testa R, Nichols WW. The in vitro activity of ceftazidime-avibactam
132 against 417 Gram-negative bacilli collected in 2014 and 2015 at a teaching hospital in São Paulo, Brazil.
133 *Braz. J. Infect. Dis. Off. Publ. Braz. Soc. Infect. Dis.* 2017;21:569–73. doi: 10.1016/j.bjid.2017.03.008
- 134 7. Biagi M, Wu T, Lee M, Patel S, Butler D, Wenzler E. Searching for the Optimal Treatment for Metallo- and
135 Serine- β -Lactamase Producing Enterobacteriaceae: Aztreonam in Combination with Ceftazidime-avibactam
136 or Meropenem-vaborbactam. *Antimicrob. Agents Chemother.* 2019 30;doi: 10.1128/AAC.01426-19

137

138

139

140

141

Figure 1




Figure 2

